ABOUT US

As a biotech-focused investment firm, our prime location in a leading biotech hub, along with our global network of investors and partners, grants us access to top-tier companies shaping the future of healthcare.

This strategic position enables us to achieve asymmetric returns, aligning with our mission to drive significant impact in the healthcare sector.

Dreavent's Biotech Community Engagement

Dreavent bridges the biotech communities of the United States from coast to coast, with a presence in the East Coast's Boston and Providence, and in the Bay Area and San Diego on the West Coast. Our own biotech forums serve as critical hubs for networking, collaboration, and innovation, connecting thought leaders and pioneers across these essential tech-centric regions.

We support the development of future cures

Our investment strategy is centered on supporting the development of future cures, with a dual focus on advancing health innovations that benefit both people and the planet. We prioritize minimizing risks by employing a carefully crafted approach to our investment decisions. This involves partnering with large funds to mitigate financial uncertainties and aligning with major pharmaceutical companies to invest in technologies with proven potential.

In our pursuit of safety and reliability, we commit to investing in companies whose products have already been successfully tested on animals and are in production using established methods. Our investment strategy is further defined by collaborating exclusively with those pharmaceutical companies and funds that have demonstrated a track record of positive outcomes, ensuring that we partake in ventures that are not only promising but also grounded in a history of success.

Dreavent Engine 2026

Opening H2 2024

Request more info

Dreavent Fund

7 Companies

Active

Voices of success

  • "Dreavent led our Series C, financing Elicio in a historically difficult biotech financing era, working with us for a full year-plus relentlessly, over several closes. Since the Series C closed in 2022 Dreavent has been incredibly supportive and resourceful, making connections with other investors and potential business development partners. They are incredibly responsive, creative, with great sense of urgency, and worldwide networks. I’ve been a CEO for 24 years and I have never worked with an investor who was so invested in the success of my company, with a “whatever it takes” mentality. It feels very much like they are on the team, not just an investor- true believers. They are also just good people which makes working through the tough issues so much easier. I could not recommend anyone more highly."

    Robert T. Connelly - CEO - Elicio Therapeutics

  • "Therini Bio is thrilled to have Dreavent join our Series A financing. After taking time to thoughtfully get to know the management team and our plans, Dreavent fully committed to Therini’s long-term vision for developing fibrin-targeting therapeutics intended to halt neuroinflammation in diseases including neurodegenerative and retinal diseases. The diligence process was efficient, with clear communication and high degree of transparency from the Dreavent team. They are also understanding about changes that inevitably arise in an early stage company like ours. Gorka has already become a strong supporter and trusted partner to Therini, making helpful introductions for the company through his broad investor network. We appreciate Dreavent’s investment and continued support!" -

    Tara Nickerson - CEO - Therini BIo

  • “Dreavent has been a very supportive investor in Inspirna since 2022. Their diligence process was straightforward and efficient, and they are transparent throughout. Dreavent’s long term focus was helpful as Inspirna seeks to tackle difficult problems in cancer metastasis and progression. Our company is pleased to count Dreavent as an institutional investor and we look forward to continuing to work with Gorka Fius and Bill Korinek as Inspirna seeks to bring new first-in-class cancer medicines to patients.”

    David Darst - COO/ CFO - Inspirna

  • "Having raised a venture capital fund and invested in early stage life science companies as a venture capitalist and now leading an innovative, next-generation mRNA company, as CEO, I recognize how important having a committed, talented venture team like Dreavent is to the success of companies like Chimeron Bio. Capital is an essential ingredient, but multifold more impactful when underpinned by the vision, expertise and non-financial resources that Dreavent brings with its investment."

    Kevin Heyeck - CEO - Chimeron Bio

  • "As CEO of Aardvark Therapeutics, Inc., I would like to convey gratitude and appreciation for the support and steady conviction of Dreavent. Since their investment into Aardvark’s Series B, it was clear that the Dreavent team was driven by a rational long-term approach vs only a quick incremental win. Importantly, Dreavent has been continually supportive in ways beyond their investment, leveraging their extensive network and making strategic introductions whenever the opportunity arose. It has been a pleasure and a positive experience working with Dreavent."

    Tien Lee, M.D. - CEO Aardvark Therapeutics

  • "I'm doing everything that I did before my diagnosis. I can di anything that I want. I can walk long distances; I can swim and I can ride my bike again" -

    Samara Rahman - Elicio Therapeutics Pancreatic Cancer Patient

  • "Working with this team has proven their reliability in decision-making. They consistently demonstrate thorough analysis and a deep understanding of the investment landscape, which has significantly contributed to our success. Their expertise and solid judgment have made them invaluable partners."

    Bill Korinek - CEO of Astrocyte Pharmaceuticals